Loading stock data…
4568.T
TSE¥2,687+38.00 (+1.43%)
Market OpenUpdated 10:30 PM EDT
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Daiichi Sankyo Company, Limited in the Healthcare sector is trading at ¥2,687. The stock is currently near its 52-week low of ¥2,443, remaining 18.2% below its 200-day moving average. Technical signals show neutral RSI of 40 and bearish MACD signal, explaining why 4568.T maintains its current current market pressure. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 40) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price¥2,687
Potential Upside
16%
Whystock Fair Value¥3,116
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus16 analysts
Mean target¥4,521+68.3%
Range¥3,050 – ¥6,000
Fundamentals
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or g...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
¥5.12T
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
18.67
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.17
Div Yield
Strong income play. Yield provides a meaningful total return floor.
274.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.27%
Volume
Today's trading volume
6.50M
Recent News
Daiichi Sankyo and Waiv partner for ADC biomarkers
The platform will be applied to identify potential biomarkers linked to treatment response prior to upcoming trial phases.
A Look At Daiichi Sankyo Company (TSE:4568) Valuation As Oncology Pipeline Drives Undervalued Thesis
Why Daiichi Sankyo Company (TSE:4568) is on investors’ radar today Daiichi Sankyo Company (TSE:4568) has attracted attention after recent share moves, with a 1.4% gain over the past day and a 5.0% rise over the past week, contrasting with weaker month and past 3 months returns. See our latest analysis for Daiichi Sankyo Company. That short burst of strength sits against a weaker backdrop, with a 30 day share price return of 9.1% and a year to date share price return of 25.6%. Meanwhile, the 1...
Health Care Roundup: Market Talk
Find insight on Novartis, AstraZeneca, Roche and more in the latest Market Talks covering Health Care.
Citi sees Daiichi supply review as immaterial for AstraZeneca
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), the FTSE 100 pharmaceuticals giant, faces no material risk from its Japanese partner Daiichi Sankyo's decision to delay its full-year 2025 results, according to Citi, which maintains a 'buy' rating on the stock. Daiichi Sankyo, which partners with...
Nuvation Bio (NUVB) Stock More Than Doubles Year-on-Year
Nuvation Bio, Inc. (NYSE:NUVB) is one of the 10 Best Small-Cap Biotech Stocks According to Hedge Funds. The stock’s price more than doubled from a year ago, up 156.7%, while it registered a 40.79% increase year-to-date. On April 16, Wedbush analyst David Nierengarten maintained a Buy rating on Nuvation Bio with a price target of […]